Sa1113 Is Intravenous Immunoglobulin (IVIG) Therapy Beneficial in Reducing Utilizations of Healthcare Resources in Patients With Drug and Device Refractory Symptoms of Gastroparesis?

      This paper is only available as a PDF. To read, Please Download here.
      To read this article in full you will need to make a payment
      AGA Member Login
      Login with your AGA username and password.

      Purchase one-time access:

      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect